Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.67 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3284203 | 0.87 | AR (0.65) | ARNR3C1ADRA2AALDH1A1LMNA | |
| SCHEMBL3910141 | 0.85 | AR (0.72) | ARNR3C1ADRA2AALDH1A1LMNA | |
| SCHEMBL3283581 | 0.83 | NR3C1 (0.65) | ARNR3C1ALDH1A1LMNACYP3A4 | |
| SCHEMBL6565555 | 0.83 | AR (0.69) | ARNR3C1ADRA2AALDH1A1LMNA | |
| SCHEMBL3966916 | 0.83 | NR3C1 (0.65) | ARNR3C1ALDH1A1LMNACYP3A4 | |
| SCHEMBL6249986 | 0.81 | AR (0.67) | ARNR3C1ADRA2AALDH1A1LMNA | |
| SCHEMBL3288674 | 0.80 | AR (1.00) | ARNR3C1BACE1MAOB | |
| SCHEMBL3284563 | 0.80 | AR (1.00) | ARNR3C1BACE1MAOB | |
| SCHEMBL12273326 | 0.78 | AR (0.63) | ARNR3C1ADRA2AALDH1A1LMNA | |
| SCHEMBL12272913 | 0.78 | AR (0.63) | ARNR3C1ADRA2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1521733-B1 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR | PFIZER PROD INC (US) | 2014-08-20 | — | — | EP | disclosed |
| US-7553877-B2 | Use of 2-hydroxy-1,2,3,4,4a,9,10,10a-octahydrophenanthrene compounds glucocorticoid receptor agonists to treat certain inflammatory conditions such as arthritis, asthma | PFIZER, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7138406-B2 | Antiinflammatory agents; antiallergens; vision defects; anticancer agents; gastrointestinal disorders | PFIZER, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-20060247264-A1 | Use of 2-hydroxy-1,2,3,4,4a,9,10,10a-octahydrophenanthrene compounds glucocorticoid receptor agonists to treat certain inflammatory conditions such as arthritis, asthma | PFIZER INC | 2006-11-02 | — | — | US | disclosed |
| EP-1521733-A1 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR | Pfizer Products Inc. (US) | 2005-04-13 | — | — | EP | disclosed |
| US-20040138262-A1 | Antiinflammatory agents; antiallergens; vision defects; anticancer agents; gastrointestinal disorders | PFIZER INC. | 2004-07-15 | — | — | US | disclosed |
| WO-2004005229-A1 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR | PFIZER PRODUCTS INC. (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247264-A1 | Use of 2-hydroxy-1,2,3,4,4a,9,10,10a-octahydrophenanthrene compounds glucocorticoid receptor agonists to treat certain inflammatory conditions such as arthritis, asthma | NR3C1, NR3C2, LTB4R2 | AR 162/4885NR3C1 1/4885ADRA2A 112/4885 |
| US-20040138262-A1 | Antiinflammatory agents; antiallergens; vision defects; anticancer agents; gastrointestinal disorders | NR3C1, MC2R, FPR1 | AR 562/4885NR3C1 1/4885ADRA2A 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.